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Abstract
Background:  Highly active antiretroviral therapy produces a significant decrease in HIV-1
replication and allows an increase in the CD4 T-cell count, leading to a decrease in the incidence
of opportunistic infections and mortality. However, the cost, side effects and complexity of
antiretroviral regimens have underscored the immediate need for additional therapeutic
approaches. Statins exert pleiotropic effects through a variety of mechanisms, among which there
are several immunoregulatory effects, related and unrelated to their cholesterol-lowering activity
that can be useful to control HIV-1 infection.
Methods/design: Randomized, double-blinded, placebo controlled, single-center, phase-II clinical
trial. One hundred and ten chronically HIV-1-infected patients, older than 18 years and naïve for
antirretroviral therapy (i.e., without prior or current management with antiretroviral drugs) will be
enrolled at the outpatient services from the most important centres for health insurance care in
Medellin-Colombia. The interventions will be lovastatin (40 mg/day, orally, for 12 months; 55
patients) or placebo (55 patients). Our primary aim will be to determine the effect of lovastatin on
viral replication. The secondary aim will be to determine the effect of lovastatin on CD4+ T-cell
count in peripheral blood. As tertiary aims we will explore differences in CD8+ T-cell count,
expression of activation markers (CD38 and HLA-DR) on CD4 and CD8 T cells, cholesterol
metabolism, LFA-1/ICAM-1 function, Rho GTPases function and clinical evolution between treated
and not treated HIV-1-infected individuals.
Discussion: Preliminary descriptive studies have suggested that statins (lovastatin) may have anti
HIV-1 activity and that their administration is safe, with the potential effect of controlling HIV-1
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replication in chronically infected individuals who had not received antiretroviral medications.
Considering that there is limited clinical data available on this topic, all these findings warrant
further evaluation to determine if long-term administration of statins may benefit the virological
and immunological evolution in HIV-1-infected individuals before the use of antiretroviral therapy
is required.
Trial registration: Registration number NCT00721305.
Background
Type-1 human immunodeficiency virus (HIV-1), the etio-
logic agent of the acquired immunodeficiency syndrome
(AIDS), causes a chronic disease characterized by a pro-
gressive loss of CD4+ T cells associated with other quanti-
tative and qualitative alterations of the immune response.
Currently, HIV-1 infection is among the most important
public health problems around the world: at the end of
2007, there were around 33 million people infected, 2,5
million new cases were diagnosed and 2,1 million HIV-1-
infected individuals died as a consequence of HIV-1-
derived clinical complications [1]. In Colombia, is has
been estimated that more than 190.000 persons are
infected with HIV-1 (calculated prevalence: around
0.7%), and 24.000 deaths due to HIV-1 infection were
reported between 1987 and 2007 [1,2].
The dysregulation of the immune response appears early
during HIV-1 infection when individuals gradually lose
their T lymphocyte proliferative responses to recall anti-
gens, alloantigens and mitogens, before the severe reduc-
tion in CD4 T-cell count appears. In addition to the direct
elimination of CD4 T cells, HIV-1 impair immune func-
tion directly through the immunosuppressive effect of
viral proteins and by a state of uncontrolled immune acti-
vation that leads to immunosuppression and accelerated
CD4 T-cell death [3-5].
The current treatment for HIV-1 infection is highly active
antiretroviral therapy (HAART), which decreases viral rep-
lication and plasma HIV-1 RNA levels, allowing partial
immune restoration that associates with a decrease in the
incidence of opportunistic infections and mortality [6].
However, after HAART is discontinued there is a rebound
in viral load and a decrease in CD4+ counts to similar lev-
els than before HAART administration. In addition,
potent antiretroviral therapy administered for several
months is unable to eliminate HIV-1 tissue reservoirs
effectively and do not lead to a full recovery of the
immune response [7].
On the other hand, international guidelines for HAART
therapy in chronically HIV-1-infected adults recommend
beginning these regimens in those individuals with an
AIDS-defining illness, in HIV-1 positive pregnant women,
and in patients with a CD4+ T-cell count lower than 350
cells/μL [8]. In this sense, too many patients with an early
diagnosis of HIV-1 infection would be without antiretro-
viral therapy during several years, with a persistent viral
replication and a progressive lymphoid tissue damage,
which may affect the level of immune restoration
achieved after the late onset of HAART. Furthermore, the
cost and complexity of HAART regimens, the recom-
mended delayed beginning of HAART in adults chroni-
cally infected with HIV-1, the growing list of long-term
side effects, and the eventual development of resistance
have underscored the immediate need for additional ther-
apeutic approaches.
Statins are mainly known for their plasma cholesterol-
lowering properties and are widely used for the preven-
tion of cardiovascular diseases [9,10]. They, however, also
have pleiotropic actions through a variety of mechanisms,
among which there are several virological and immu-
noregulatory effects that are unrelated to their cholesterol-
lowering activity [11-13]. Depletion of cholesterol alters
the capacity of a cell to form lipid rafts, and numerous
studies have shown that HIV-1 requires lipid rafts for sev-
eral key stages of its replication cycle [14,15]. Moreover,
some evidence suggests that statins alter the intracellular
signals dependent on Rho GTPases [16], the functional
activity of LFA-1/ICAM-1 adhesion molecules [17], the
expression of the CCR5 coreceptor and the secretion of
RANTES [18], and may exert significant modulatory
effects on the balance of the cytokine network in human
beings [19,20]. Based on these immunomodulatory prop-
erties, statins are being evaluated in the treatment of dis-
eases beyond classic cardiovascular conditions [21].
Therefore, statins therapy might modulate the immune
system function in HIV-1-infected individuals, affecting
the clinical course of this infection. Whether these obser-
vations translate into significant clinical interactions is
uncertain, and very limited clinical data are available on
this topic.
We hypothesize that the long-term use of statins will ben-
efit the overall evolution of HAART naïve HIV-1-infected
individuals, having the following effects: i) decreasing
plasma viral load; ii) increasing blood CD4 T-cell count;
iii) restoring the immune system function; and iv)
decreasing the frequency of morbidity and mortality. To
evaluate this hypothesis, this investigation is aimed toTrials 2009, 10:41 http://www.trialsjournal.com/content/10/1/41
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explore the effect of lovastatin (oral intake, 40 mg/day
during one year) on viral load and CD4 T-cell count,
adaptive immune parameters, cholesterol metabolism
and Rho GTPases function, and clinical evolution of
chronically HIV-1-infected individuals who are HAART
naïve.
Methods/design
Study Design
Randomized, double-blinded, placebo-controlled, phase
II clinical trial.
Study Population
One hundred and ten (110) chronically HIV-1 infected
patients without antiretroviral treatment.
The inclusion criteria will be the following:
- Asymptomatic HIV-1 positive individuals, with age ≥ 18
years, who are HAART naive
- HIV-1 infection confirmed by: a) any positive western
blot at least six months before admission to the study; or
b) within the last six months by a western blot that
includes the p31 and p66 bands
- Detectable viral load but less than 100,000 copies/mL
- CD4+ T cell count ≥ 350 cells/μL
The exclusion criteria will be the following:
- Inability or unwillingness of patients to give written
informed consent
- Main residence outside Medellin and its metropolitan
area, or any indication of difficulties in the follow-up
period
- Participation in other clinical trials
- Evidence that the patient will exhibit low adherence to
intervention and follow-up (Morisky-Green test)
- Pregnancy or breastfeeding
- Any type of antiretroviral treatment before admission to
the study, and therapy with lipid-lowering drugs during
the last six months
- Antecedents of allergy, contraindications or intolerance
to statins
- Patients receiving medications which can generate rele-
vant interactions with lovastatin: clarithromycin, erythro-
mycin, azithromycin, itraconazole, ketoconazole,
nefadozone, cimetidine, rifampin, phenobarbital, car-
bamacepin, phenitoin, gemfibrozil.
- Unwillingness to avoid the consumption of Citrus para-
dise (grapefruit juice) or Saint John's Wort (Hypericum)
- Chronic active hepatitis (B or C)
- Any hepatocellular disease, indicated by elevation of
liver enzymes (AST or ALT) more than twice the upper
limit of reference values
- Renal failure, indicated by serum creatinine ≥ 2 mg/dL
- Myopathy, indicated by an elevation of creatine phos-
phokinase (CPK) more than five times the upper limit of
reference values
- Infection or acute disease that requires inpatient treat-
ment
- Active substance-related disorders.
- Medical indication for using lipid-lowering drugs
Randomization
The treatment assignment ratio will be 1:1, fixed through-
out the study. The allocation sequence will be developed
by a statistician in the Data Coordinating Center (DCC)
using randomly permuted blocks of size 2, 4 and 6 gener-
ated by a random number generator (ralloc program, Stata
co. 8.2, College Station, TX, USA). Once the sequence is
generated, it will be matched with sequential numbers
between 001 and 110 and given to the manufacturer for
labelling the blisters containing the pills with lovastatin or
placebo. The allocation sequence will remain in a confi-
dential file in the DCC unknown for the clinician investi-
gators, the patients, and the pharmacists who dispensed
the interventions. This sequence will be disclosed only
after study termination for data analysis, or at request by
the Data Safety Monitoring Board (DSMB).
Allocation concealment mechanism
The manufacturer will deliver both interventions (lovasta-
tin and placebo) to the clinical investigators labelled only
with the number code assigned from the list given by the
DCC. Neither the investigators nor the pharmacists will
know the actual content of the pills, as they will be con-
tained in identical blisters and their physical characteris-
tics will be the same (size, shape, colour and smell). The
complete treatment course for one year, dispensed
monthly, will be packed in sealed boxes equally labelled
with the corresponding number, unique for each partici-
pant. Each treatment will be allocated and opened onlyTrials 2009, 10:41 http://www.trialsjournal.com/content/10/1/41
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for the sequential participant intended to enrol after the
verification of eligibility criteria. The pharmacists will
handle the interventions and will be responsible for their
maintenance under lock and key. The dosage for lovasta-
tin is 40 mg per day, represented by two pills to take each
night; for this reason both interventions will be dispensed
to fulfil two pills per night.
Clinical follow-up
Before the enrolment and monthly during the study, all
the patients will have a complete clinical evaluation per-
formed by a physician who is blinded for the intervention
assigned to each patient. Before the intervention (day 0)
and 30, 180 and 360 days of study, blood samples will be
collected to perform laboratory analysis (transaminases,
CPK, serum lipid profile). The intervention will be
stopped in presence of serious adverse events, a three-fold
increase in serum transaminases or a five-fold increase in
CPK. In order to preserve the blinding process, only the
first value of serum lipid profile (day 0) will be known by
the clinical investigators (eligibility criteria). Afterwards,
for the samples at 180 and 360 days of following, a med-
ical safety monitor in the DCC will receive the report
directly from the laboratory.
The following clinical and pharmacotherapy parameters
will be evaluated monthly for one year, during the medi-
cal control visits:
- Tolerance to medications and adverse events
- Adherence to therapy (lovastatin or placebo) and pre-
vention of withdrawals
- Incidence of infections (opportunistic and non-oppor-
tunistic)
- Incidence of non-infectious diseases defining AIDS
- Hospitalizations due to diseases related to progressive
HIV-1-infection
- Death due to diseases related to progressive HIV-1-infec-
tion
Interventions and safety of statins
After the first medical appointment and then monthly,
each participant will receive the whole therapy for 1
month (60 tablets of lovastatin or placebo) from the phar-
macist who also evaluates adherence to the intervention
and gives usage recommendations. The statins are well
tolerated by most persons; they have proven to be
extremely safe in the vast majority of patients. Few signif-
icant side effects have been observed in clinical trials, and
post-marketing reports of adverse events have been very
limited when considered in comparison to a very large
number of persons safely using them. The main risks of
statins are elevation of hepatic enzymes, and myopathy.
Elevated hepatic transaminases generally occur in 0.5% to
2.0% of patients and are a dose-dependent effect; progres-
sion to liver failure specifically due to statins is exceed-
ingly rare. Myopathy induced by stain is also rare. Mild
gastrointestinal symptoms (e.g., constipation, flatulence,
dispepsia, and abdominal pain), are the most common
adverse effects of lovastain. Thus, a lovastatin dose of 40
mg/day is well tolerated with low discontinuance rates
(lower than 2%). [22]
Retention and adherence to the trial
The study is conducted in the outpatient services from the
most important centres for health insurance care in the
city of Medellín (northwest region of Colombia). The staff
physicians are informed of the study protocol and they are
attentive to eligibility criteria in their daily consultation.
Once a potential participant is detected, her/his attending
physician will give her/him information regarding the
clinical trial and ask for permission to give both complete
identification (full name, identity number) and contact
phones (main and alternative) to the trial coordinators.
They will call those potential participants and invite them
to an informative meeting with the clinical investigators.
In this interview, eligibility criteria should be applied
including laboratory screening. When the results come
out, they are sent to the trial coordinator who should
again contact the potential participant for a recruiting
visit, in which informed consent will be signed.
To keep permanent contact with potential and recruited
participants, the trial coordinator will be available
through a 24-hour mobile phone and e-mail messaging.
Also, she should maintain a constant two-way communi-
cation with the HIV-attention program to constantly
detect new potential candidates. At the end of each con-
sultation, the next appointment will be scheduled in
advance, giving a card with emergency phones and infor-
mation. All participants will be contacted by the trial coor-
dinator at least two days before the scheduled visit to
confirm it and to re-schedule, if necessary. If any of the
potential or recruited participants are not available, an
active search for updated contact information should be
performed beginning by reviewing the health insurance
database and also calling the alternative phone numbers
provided. Special attention should be given to the basal
condition of individuals at the time of the programmed
laboratory tests. Recommendations are given in each con-
sultation, and the participants will be encouraged to call
the trial coordinator to solve doubts or questions any
time.Trials 2009, 10:41 http://www.trialsjournal.com/content/10/1/41
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Study outcomes
The efficacy of lovastatin to control HIV-1 replication
allowing an improved immune reconstitution will be
determined by primary and secondary outcomes. The pri-
mary outcome will be the viral load measured as RNA
copies per mL of peripheral blood, and the secondary out-
come will be the CD4 T-cell count measured as cells per
μL of peripheral blood; both determined at enrolment,
and 6 and 12 months after the intervention.
The tertiary or exploratory outcomes will be the following
(determined at enrolment, and 6 and 12 months of inter-
ventions, unless indicated otherwise):
- Absolute number per μL of peripheral blood of CD8+ T
lymphocytes and the CD4/CD8 ratio
- Basal expression of immunological activation markers
(CD38 and HLA-DR) on CD4+ and CD8+ T lymphocytes
- Concentration of total serum cholesterol
- Concentration of cellular cholesterol
- Functional activity of LFA-1 and ICAM-1
- Activity of Rho GTPases
- Monthly frequency and type of: infections, non-infec-
tious AIDS defining diseases, hospitalizations
- Mortality due to an HIV-1/AIDS related cause
Laboratory assays
Viral load
The plasma HIV-1 viral load will be determined using the
commercial assay "RT-PCR Cobas Ampliprep-Cobas
Amplicor" (Roche, Indianapolis, IN).
Flow cytometry
Mouse fluorochrome-labeled monoclonal antibodies
(mAbs) against the following human molecules will be
used: CD3, CD4, CD8, CD38 and HLA-DR; these antibod-
ies and the corresponding isotype control antibodies will
be from Becton Dickinson-Pharmingen (San Jose, CA).
Frequency and phenotype of T-helper cells (defined as
CD3+/CD4+ lymphocytes) and T-cytotoxic cells (CD3+/
CD8+ lymphocytes) will be determined by three or four-
color flow cytometry. For cell surface staining, 100 μL of
anti-coagulated whole blood will be incubated with the
corresponding specific fluorescence labelled mAbs for 20
min/RT in the dark. The erythrocytes will be lysed by incu-
bating for 10 min with 2 mL of 1× FACS lysing solution
(Becton Dickinson); then, cell suspension will be centri-
fuged for 5 min at 250 × g, the supernatant will be dis-
carded and the cells will be washed twice with 2 mL of
cold PBS at 250 × g/5 min. Finally, cells will be fixed with
250 μL of 2% formaldehyde.
The absolute number of the different T-lymphocyte sub-
populations will be calculated on the basis of manually
determined total and differential peripheral blood cell
counts. For all experiments, appropriate isotype-matched
control antibodies will be included. During the acquisi-
tion, 5 × 104 total cells will be analyzed. Dead cells will be
gated out by forward and side scatter. Flow cytometry will
be performed using the Becton Dickinson FACSORT
instrument and analyzed with Cell Quest software.
Concentration of serum total cholesterol, transaminases and CPK
The serum concentration of total cholesterol will be meas-
ured by colorimetric enzymatic assay; the concentration
of hepatic transaminases will be determined by immuno-
turbidimetry, while the serum levels of CPK will be deter-
mined by a dry chemical assay.
Cellular cholesterol measurement
Cellular cholesterol content will be measured with a cho-
lesterol oxidase-based fluorometric assay (Amplex Red
Cholesterol Kit) from Molecular Probes (Eugene, OR).
Cholesterol content of cells will be normalized to total
cellular protein.
Assay to evaluate the adhesive function of LFA-1/ICAM-1:
HIV-1 binding to immunoadhesins will be measured in
virus capture assays carried out as previously described
[23]. High protein-binding 96-well plates (Costar, Cam-
bridge, MA) will be coated with goat anti-human IgG (Fc
specific) at 4°C overnight (100 μL/well, 10 μg/mL in 50
mM Tris, pH 9.5). Supernatants will be removed and the
plates will be then blocked by adding 200 μL of 3% heat-
inactivated bovine serum albumin in PBS to the wells for
1 hr at 37°C. After washing the wells with PBS, 100 μL of
supernatants containing ICAM-Ig or VCAM-Ig (6 to 10
mg/mL) will be added to the wells for 1 hr at 37°C. The
wells will be washed with cRPMI before adding 100 μL of
cell-free virus (20 to 40 ng of p24 per mL) and incubating
the plates for 1 hr at 37°C. The wells will be washed three
times with cRPMI and 1% Triton X-100 in PBS will be
then added to the wells to lyse bound virus. Virus quanti-
tation will be carried out by p24 ELISA on the lysates.
Rho activation assay
The Rho activation assay will be performed as described
[16]. Briefly, 3 × 106 peripheral blood mononuclear cells
(PBMCs) will be incubated with HIV-1 stocks; then,
PBMCs will be washed with ice-cold PBS and lysates will
be prepared using Rho activation assay kits (Upstate Bio-
technology). GTP-bound Rho will be precipitated with
RBD agarose beads, and measured in pellets by WesternTrials 2009, 10:41 http://www.trialsjournal.com/content/10/1/41
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blot with specific antibodies, using crude cell extracts for
normalization.
Biostatistical considerations
Primary hypothesis: The use of lovastatin (40 mg/day dur-
ing one year) compared with placebo in HIV-1-infected
individuals who are naïve for HAART, should result in a
reduction of 50% or higher in viral load and an increase
of 20% or higher in CD4 T cell count.
Documentation of outcome and follow-up: Primary and
secondary outcome measures will be documented by
investigators and research assistants masked to the sub-
ject's intervention group assignment.
Sample size and power: Based on a pilot test performed
on 40 patients treated at the infectious diseases service,
Hospital Universitario San Vicente de Paul (Medellin,
Colombia), the baseline values for the primary and sec-
ondary outcome measures are as follows:
Mean viral load = 55,000 copies/mL; SD = 80,000 copies/
mL
Mean CD4+ T cell count = 500 cells/mL; SD = 180 cells/
mL
These outcomes, determined 6 and 12 months after the
intervention, are longitudinal data with correlated meas-
urements, and they need special considerations for calcu-
lation of power and sample size. In addition to the usual
requirements of type I error, type II error, variation meas-
urement and meaningful difference to be detected in lon-
gitudinal studies, it is necessary to know the number of
repeated observations and an estimate of the correlation
among them. The meaningful difference may be expressed
as a time-averaged difference in response between groups.
Assuming a fixed correlation of 0.8 among the three dif-
ferent measures of viral load, and a time-average differ-
ence of 50% between groups (i.e., a decrease of 22,500
copies/mL from the baseline value), with an alpha error of
0.05 and a beta error of 0.2, the sample size required is 55
patients per group. This sample size has more than 90%
power to detect an increase of at least 20% in the baseline
CD4+ T cell count. There will be not corrections for losses
to follow-up or non-adherence, as the study is intended as
a pilot phase II trial.
Interim monitoring
An independent DSMB comprising three members with
expertise in statistics, epidemiology and infectious dis-
eases will be responsible for the interim monitoring proc-
ess. The statistician at the Data-Coordinating Center will
be the only person with access to the full database and he
will provide the required information, both overall for the
interim quality assurance and specific by treatment group
(efficacy and safety) exclusively for the DSMB. The first
interim monitoring will be conducted when the study par-
ticipants complete six months of evaluation. The second
interim analysis will be conducted when all the patients
complete nine months of evaluation. Stopping guidelines
for efficacy monitoring will be determined for the primary
and secondary outcomes according to the modified
O'Brien-Fleming procedure. With this procedure, the val-
ues for statistical significance are 0.0006 and 0.0151 in
the first (α1) and second (α2) interim analyses, respec-
tively, for a final significance (α) of 0.0471. Stopping
guidelines for safety are left at discretion of the DSMB,
with an expected rate of adverse events (hepatic or muscle
enzymes elevations) less than 1%. Stopping guidelines
regarding futility are not considered and this was agreed in
a meeting with the DSMB.
Analysis plan
The overall efficacy will be established with an intention-
to-treat principle, in which the patients will be analyzed in
the treatment group to which they were assigned by rand-
omization. The outcomes viral load and CD4 T cells
count, as well as most of tertiary/exploratory outcomes,
are longitudinal data with repeated measurements and
they require special statistical methods to account for the
correlation among observations. To analyze this kind of
clustered data it is necessary to model both the regression
of Y (the outcome measure) on x (the intervention) and
the within-cluster dependence. In a marginal model, the
regression of Y on x and the within-cluster dependence are
modelled separately with the application of the statistical
method called generalized estimating equations (GEE),
which was designed to provide valid regression inferences
with correlated data [24].
When the regression analysis for the time-averaged differ-
ence in response between groups is the primary interest, as
for our research, the β coefficient can be estimated by solv-
ing the estimating equation
Where μi(β) = E(Yi), the marginal expectations for Yi is a
vector, which comprises the mi observations (number of
measurements) from the ith cluster (each patient). The
marginal expectation is the average response over the pop-
ulation of individuals with a common value of x (lovasta-
tin or placebo). The covariance matrix, Cov(Yi), for Yi
depends not only on β but on α, which characterizes the
within-cluster dependence or correlation among observa-
tions. This additional problem can be overcome by iterat-
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ing until convergence between solving 
and updating  , an estimate of α [24]. This estimate
of α may be approximated by the observed correlations in
the data and by the assumption of the same correlation
among pairs of mi observations (i.e. an exchangeable cor-
relation structure). Additionally, the use of a robust vari-
ance estimator (Huber-White) produces valid standard
errors even if the correlations within group are not as
hypothesized by the specified correlation structure [25].
The GEE approach is simply to choose parameter values
 so that the expected μi(β) is as close to the observed Yi
as possible, weighting each cluster of data inversely to its
variance matrix, Cov(Yi; β, α), which is a function of the
within-cluster dependence. These models have been used
in the analysis of some interventions to prevent HIV infec-
tion in African American adolescents [26], and to evaluate
the effect of interventions on outcomes related not only
with HIV infection but other sexually transmitted dis-
eases.
The β coefficient obtained with this procedure for the X
variable is the estimated time-averaged change in the out-
come measure in the lovastatin group compared with pla-
cebo, and its p-value is given by the Wald statistic
. We will use the xt of commands
from the statistical package Stata (StataCorp, 2007:
Release 10, College Station, Texas, USA) for the proposed
analysis of cross-sectional time-series datasets. Specifi-
cally, the command xtgee will evaluate population-aver-
aged panel-data models using GEE. Although the
expectation is that randomization assists in balancing
known and unknown prognostic factors in a randomized
clinical trial, this assignment process is not a guarantee
against the possibility that estimates of treatment effect be
modified by covariate imbalance. Accordingly, the esti-
mated time-averaged change in the outcome measure for
lovastatin vs. placebo will be adjusted by the most impor-
tant prognostic factors (baseline CD4+ T cell count, base-
line viral load, and adherence to the treatment)
considered as additional independent variables in the
same GEE model.
IRB approvals
The protocol and the informed consent document were
reviewed and approved by the Ethics Committee respon-
sible for oversight the study (Sede de Investigacion de la
Universidad de Antioquia, Medellin, Colombia).
Discussion
The immunopathogenesis of HIV-1 infection involves
multiple interactions between the virus and host's
immune system. Although there is in vivo activation of
both, innate and adaptive immune responses [5], the
HIV-1 infection is fought with limited success. In fact,
despite of more than two decades of research directed to
induce adaptive immune responses to HIV-1, no success-
ful immunological therapy or vaccine has been devel-
oped.
The current therapy for HIV-1 infection is HAART, which
blocks HIV-1 replication and decreases the incidence of
opportunistic infections and mortality [6]. However, the
toxicity and long-term side effects of HAART regimens,
and the eventual development of resistance have under-
scored the immediate need for additional therapeutic
approaches, which may control effectively the HIV-1 rep-
lication and exhibit immunomodulatory properties
required to counteract the immune dysregulation
observed in chronically HIV-1-infected individuals.
Statins are competitive analogues of the substrate of 3-
hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase; this enzyme catalyzes the conversion of
hydroxyl-methyl-glutarate into mevalonic acid, a precur-
sor for the biosynthesis of cholesterol and isoprenoids
molecules (geranylgeranyl- pyrophosphate and farnesyl-
pyrophosphate, two donors of protein prenylation) [27].
Statins are primarily used as hypolipidemic agents for
reducing plasma cholesterol levels and, consequently, for
preventing cardiovascular diseases; they are considered
very safe if not taken in combination with other drugs
sharing the same metabolizing pathways. These products
are also administered in the treatment of dyslipidemia
associated with AIDS and HAART and of lipodystrophy
associated with antiretroviral drugs, particularly protease
inhibitors (PIs) [9,10]. The beneficial effects of statins also
depend on mechanisms other than cholesterol reduction
[28]. For example, statins improve endothelial function,
reduce blood thrombogenicity, modulate inflammatory
responses, and exert recently described immunomodula-
tory actions [11,28,29].
Four main mechanisms are known to explain the various
immunomodulatory effects of statins. The first two are
based on the inhibition of HMG-CoA reductase described
above. Blockage of the mevalonic pathway reduces syn-
thesis of cholesterol and non-sterol isoprenoid products,
leading to cholesterol reduction in plasma and cell mem-
branes (mainly in lipids rafts) [27], and inhibiting pre-
nylation of Rho and Ras GTPases affecting actin
cytoskeleton rearrangement and intracellular signalling
[16]. The third mechanism is unrelated to inhibition of
HMG-CoA reductase, and consist in blocking the interac-
tion between LFA-1 and ICAM-1 adhesion molecules [30],
which is crucial to stabilize antigen presenting cell/T-cell
contact during antigen presentation and to regulate the
traffic of leukocytes during homeostatic and inflamma-
U1 0 βα β , () ⎡ ⎣ ⎤ ⎦ =
ˆ αβ ()
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tory conditions [31,32]. Finally, the fourth mechanism is
the modulation by statins of surface molecule expression
and protein secretion; statins inhibit MHC class-II mole-
cule expression on antigen presenting cells and endothe-
lial cells [13], and CCR5 expression on T lymphocytes
[18], while increases the secretion of RANTES and other
cytokines [18].
These pleiotropic effects of statins that are related and
unrelated to their cholesterol-lowering properties might
explain certain positive clinical and laboratory observa-
tions, particularly in cardiac and kidney transplantation
[33] and ischemic strokes [34]. Few clinical studies have
addressed specifically the anti-HIV-1 activity of statins
[16,35-38], and some controversial results have been
obtained. In the study performed by del Reat et al., six
asymptomatic chronically HIV-1-infected patients not
receiving HAART were given lovastatin for a month as
their only medication [16]. This short-term statin treat-
ment clearly reduced serum viral RNA loads in all patients
and increased their CD4 T-cell counts. Discontinuation of
treatment was followed by a rebound in viral load.
The study carried-out by Waters et al. evaluated HIV-1-
infected individuals on first-line HAART, and showed no
statistically significant difference between viral load
rebound and blips in patients on stable HAART who did
and did not receive statins [38]. They suggested that when
patients achieve full viral suppression with their first-line
therapy, any small effect of non-HAART medication
would be difficult to detect. However, it must be noted
that the well known potency of HAART in significantly
reducing HIV-1 loads will most likely mask any statin-
mediated inhibition of viral production. They concluded
that larger studies with longer follow-up and studies in
patients with detectable viremia receiving and not receiv-
ing HAART are necessary to determine the real viral effect
of statins and whether they confer any measurable benefit
or harm to patients. On the other hand, other independ-
ent study reported that no anti-HIV-1 activity in vitro was
detected at subtoxic concentrations of several statins
(atorvastatin, simvastatin, fluvastatin and lovastatin)
[35]. Furthermore, descriptive and not blinded evalua-
tions in HIV-1-infected patients on HAART reported that
simvastatin or pravastatin, administered during 12 or 8
weeks respectively, did not induce a significant change in
the mean viral load or CD4+ T-cell count [35,36].
The biological effects of statins on cholesterol metabo-
lism, Rho GTPases activity, LFA-1/ICAM-1 function and
CCR5/RANTES expression can disrupt several steps of the
HIV-1 life cycle, and target cell membrane interaction.
HIV-1 binding and entry are achieved through spatial and
temporal tuning of protein interactions at the plasma
membrane level, which often leads to cell signalling
events that favour pathogen infection [39]. Also, numer-
ous studies have shown that HIV-1 requires lipid rafts for
several key stages of its replication cycle, and depletion of
plasma membrane cholesterol has been shown to inhibit
HIV-1 entry and infection in both cell lines and primary
cells [14,40]. During HIV-1 infection, CD4 and CCR5 act
as the primary cell surface receptor and coreceptor; their
engagement by viral gp120 results in T cell activation by
recruiting p56lck [41]. It has been shown that CD4 local-
ization in lipid rafts is required for p56lck activation and
HIV-1 entry [15]. Cholesterol has also been shown to be
critical for CCR5 and CXCR4 conformation and function
[42]. On the other hand, HIV-1 binding and internaliza-
tion into immature dendritic cells have been shown to be
dependent on lipid rafts through a cholesterol-dependent
pathway [43].
Fusion of viral envelope and plasma membrane of target
cells is the step that follows HIV-1 attachment. Even
though the mechanism of membrane fusion remains to
be fully understood, the cholesterol present in the viral
envelope has been shown to play an important role in this
process [44]. Removal of cholesterol from mononuclear
cells reduces CD4 and CXCR4 co-localization with actin
and cell susceptibility to virus-induced membrane fusion
[45]. The capacity of HIV-1 to initiate fusion of mem-
branes may rely heavily on the ability of gp41 to bind to
cholesterol and get positioned in lipid rafts [46]. The
transmembrane envelope gp41 possesses a signal
sequence capable of targeting lipid domains thought to be
important in gp41-dependent membrane fusion [47].
Cholesterol-dependent events also play a prominent role
during later steps in the HIV-1 life cycle, such as assembly,
budding and maintenance of virus morphology and infec-
tivity [48]. Cholesterol is an integral constituent of the
viral membrane, and thus participates to its structure; the
virions being formed must acquire it from the host cell.
Cholesterol depletion of HIV-1-infected cells results in a
significant decrease of virus release, and the virions
released from those cells have little infectious potential
[49]. HIV-1 particles can incorporate the adhesion mole-
cule ICAM-1 due to an association between the cytoplas-
mic domain of ICAM-1 and Pr55Gag; in fact, the physical
presence of host-derived ICAM-1 is known to increase
virus infectivity [50]. When emerging from their host cell,
newly formed viruses must interact again with the plasma
membrane of the host cell and lipid rafts have again been
shown to be specifically involved in viral budding [51].
The viral regulatory protein Nef has been shown to bind
cholesterol, transport newly synthesized cholesterol to the
site of viral budding, enrich lipid rafts with newly synthe-
sized cholesterol, increase the formation of lipid rafts and
promote the biosynthesis of viruses [52]. Nef expressionTrials 2009, 10:41 http://www.trialsjournal.com/content/10/1/41
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has been shown to correlate with high viral titers and dis-
ease progression; lipid raft-associated Nef has been shown
to prime T cell activation through IL-2 secretion resulting
from CD3 or CD28 stimulation, promoting HIV-1 replica-
tion and virus spread [53].
The molecules LFA-1, ICAM-1, ICAM-2, and ICAM-3 are
all expressed on HIV-1-infected cells, and they are also
found embedded onto virions [54,55]. The expression
levels of these adhesion molecules increases with disease
progression [56]. It has been shown that the cell-to cell
contact area is largely exploited by the virus. Therefore, the
pathogenesis of HIV-1 infection can be modulated by the
ICAM-1/LFA-1 interaction through modulatory effects on
cell to-cell transmission of HIV-1, virus replication, virus-
mediated syncytium formation, depletion of CD4 T cells,
and destruction of the architecture of secondary lymphoid
organs [57-62].
All the previously cited studies indicate that almost every
aspect of the life cycle of HIV-1 relies on cholesterol. In the
absence of this steroid, HIV-1 attachment to its host cell is
severely impaired since clustering of receptors in lipid
rafts is hindered and the conformational state and func-
tion of CCR5 and CXCR4 co-receptors are critically
affected. In addition virus-cell fusion is greatly dimin-
ished, virus transcytosis is inhibited, virus production and
budding are reduced, and cell signalling is altered. The
effects of cholesterol depletion on the cell cycle are also
likely to be most detrimental to HIV-1 biology, bringing
virus gene expression to a virtual stop in CD4 T cells. The
control of cholesterol through statins is thus likely to
interfere with several key steps of HIV-1 replication, offer-
ing the possibility of new therapeutic strategies to the cur-
rent arsenal of antiviral drugs. It would be of high interest
to assess the effectiveness of statins to control virus repli-
cation based on their ability to affect cholesterol biosyn-
thesis.
Inhibition of the prenylation of Rho GTPases can also reg-
ulate the affinity state of LFA-1 and attenuate several
aspects of the immune response by modifying the intrac-
ellular signalling pathway. Inhibition of prenylation of
small GTPases by lovastatin seems to be an alternative
mechanism by which this compound might interfere with
HIV replication underlying its therapeutic potential dur-
ing HIV-1 infection [16], as well as for treatment of other
inflammatory and immunological disorders
[28,29,63,64].
It is known that the hyper-activation status of the immune
system plays a pivotal role in the evolution of the disease
in HIV-1-infected persons. In order to reduce viral load
and immune hyper-activation, statins could also be con-
sidered as virostatic agents. At the present time, a very lim-
ited number of in vitro and in vivo studies support the
possible anti-HIV-1 activity displayed by statins
[16,17,65], but, great amount of data in the literature
describe the anti-inflammatory and immunomodulatory
effects of statins in various experimental model systems
[29,64,66,67].
Conclusion
Statins could possibly act on distinct levels for controlling
HIV-1 replication: a) by lowering cholesterol, they could
slow down the cell cycle, modify several signalling path-
ways and diminish viral entry and budding; b) by inhibit-
ing the prenylation of small GTPases, they could hinder
cell movement and decrease expression or affinity level of
immune molecules such as LFA-1 and ICAM-1, c) by mod-
ulating CCR5 and RANTES expression, they could hamper
the infection of target cells by R5 tropic viruses, and d) by
blocking LFA-1/ICAMs interaction, they could attenuate
several components of inflammatory, immunologic and
virological responses. The statins could thus eventually
prove to be efficient drugs against HIV-1. These potential
antiviral and immunological properties warrant a rand-
omized clinical trial addressed to explore the clinical use
of statins in HIV-1 infected patients.
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